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Background
Receptors for the natriuretic peptides (NPs) ANP, BNP
and CNP are highly expressed in lung, suggesting that
this organ is an important physiological target for NP
signalling. By stimulating vaso- and bronchodilation and
inhibiting cell proliferation and fibrotic processes, NPs
may have therapeutic potential in various lung diseases.
Mechanisms responsible for the relatively short half-life
(few min) of NPs and the control of their local concen-
trations include (i) receptor-mediated internalization by
the so called clearance receptor (NPR-C) and (ii) degra-
dation by a membrane metalloprotease, called neutral
endopeptidase (NEP) or neprilysin [1]. The velocity of
peptide degradation/inactivation differs between ANP,
BNP and CNP. Interestingly, cleavage of NPs by insulin-
degrading enzyme (IDE) [2] may have a particular role
in NP signalling by generating peptide fragments that
are hyperactive in receptor stimulation [3].
The physiological significance of NEP was supported
by several studies in rodents showing that NEP inhibi-
tion leads to increased NP concentrations and activity.
Moreover, we found that NEP inhibition is necessary
and sufficient for detection of GC-A and GC-B by affi-
nity labelling experiments with radioactive ANP or CNP
in mouse and rat lung membrane preparations. Analo-
gous assays, however, failed to label these receptors in
human lung membranes, suggesting potent NP-degrad-
ing activity of NEP inhibitor-insensitive proteases.
Methods and results
ANP degradation by lung membranes in either the
absence or presence of NEP inhibitors was analyzed by
thin-layer-chromatography and mass spectrometry [2].
We found that NEP inhibition strongly reduces ANP
degradation by rat and mouse but not human membranes.
ANP-degrading activity in human lung membranes under
conditions of NEP inhibition was very potent and even
detectable with 1 ng of membrane protein. Like ANP,
CNP was rapidly hydrolyzed. In both peptides, initial clea-
vage occurred at the same position within the conserved
peptide ring structure being essential for biological activity.
A second cleavage each was localized to the amino-termi-
nus (behind Arg-4 or Lys-4, respectively). The cleavage
sites are unrelated to those by NEP and IDE and indicate
trypsin-like enzyme activity. Unlike ANP and CNP, BNP is
a poor substrate and shows a completely different and
complex cleavage pattern after prolonged incubation. The
NEP inhibitor-insensitive protease was also detectable,
albeit at much lower levels, in membranes from human
aorta and mesenteric arteries, but not at all in placenta.
Studies with various protease inhibitors revealed that leu-
peptin exposure potently inhibits NP degradation by this
activity.
Conclusion
A novel trypsin-like enzyme activity, but not NEP, is the
major natriuretic peptide-degrading membrane protease
in human lung. The accumulated expression of this
enzyme in human pulmonary tissue favours potential
therapeutic interventions in lung diseases. Leupeptin
may act as a beneficial agent in this regard. * Correspondence: wiebke.janssen@mpi-bn.mpg.de
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